How Investors May Respond To Ingredion (INGR) Pairing AI-Powered R&D With Dividend Stability

• On March 18, 2026, Ingredion Incorporated announced its board declared a quarterly dividend of US$0.82 per share payable April 21, 2026, and confirmed a global AI-driven R&D collaboration with Shiru to develop novel natural prebiotic and functional protein ingredients for food, beverage, supplements, and specialized nutrition customers.
• This tie-up gives Shiru access to Ingredion’s scale and 18,000-plus customer relationships across 120 countries, potentially speeding real-world adoption of AI-discovered ingredients such as next-generation prebiotics.
• Next, we’ll explore how Ingredion’s AI-enabled Shiru partnership could influence its Texture & Healthful Solutions growth narrative and competitive positioning.

Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Ingredion Investment Narrative Recap

To own Ingredion, you need to believe its shift toward higher value specialty ingredients can offset sluggish overall revenue growth and pressure on legacy starch and sweetener volumes. The new AI-enabled Shiru collaboration fits this thesis by targeting next generation prebiotic and functional protein ingredients, but it does not materially change the near term catalyst, which is execution in Texture & Healthful Solutions, or the key risk that weaker demand and pricing in core products could continue to weigh on results.

The most relevant recent announcement alongside the Shiru news is Ingredion’s reaffirmed quarterly dividend of US$0.82 per share, payable on April 21, 2026. For many investors, steady dividends and ongoing share buybacks help underpin the case for holding the stock while the company invests in AI driven ingredient discovery, even as near term sales guidance still points to only modest growth and ongoing exposure to tariffs and currency swings.

Yet investors should also be aware that reliance on new specialty ingredients to offset persistent weakness in legacy products...

Read the full narrative on Ingredion (it's free!)

Ingredion's narrative projects $7.8 billion revenue and $696.0 million earnings by 2028. This requires 2.0% yearly revenue growth and a $20.0 million earnings increase from $676.0 million today.

Uncover how Ingredion's forecasts yield a $127.00 fair value, a 14% upside to its current price.

Exploring Other Perspectives

Three members of the Simply Wall St Community currently place Ingredion’s fair value between US$127 and about US$185 per share, highlighting a wide span of expectations. You can set those views against the company’s push into AI enabled prebiotic and protein ingredients, which could influence how resilient earnings prove to be if legacy starches and HFCS stay under pressure.

Explore 3 other fair value estimates on Ingredion - why the stock might be worth just $127.00!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Ingredion research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Ingredion research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ingredion's overall financial health at a glance.

Want Some Alternatives?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Uncover the next big thing with 32 elite penny stocks that balance risk and reward.
• Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
• We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com